Amolyt Pharma Funding: $210M Raised, Series C (2023)
Amolyt Pharma is based in Lyon, France. It has raised $210M in total funding. Latest round: Series C. Backed by Sofinnova Partners, LSP, Novo Ventures.
Amolyt Pharma funding overview
Amolyt Pharma is based in Lyon, France. Amolyt Pharma has raised $210M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in January 2023. The round record for Amolyt Pharma runs through 2023; nothing later has been disclosed. Investors on record include Sofinnova Partners, LSP, Novo Ventures, Kurma Partners, OrbiMed, EQT Life Sciences and 2 others. 8 distinct backers are named across the disclosed rounds.
Amolyt Pharma at a glance
Total raised
$210M
Latest round
Series C
Latest round date
January 2023
Headquarters
Lyon, France
Notable investors
Sofinnova Partners, LSP, Novo Ventures, Kurma Partners, OrbiMed, EQT Life Sciences, Mass General Brigham Ventures, RA Capital Management
Frequently asked about Amolyt Pharma funding
How much has Amolyt Pharma raised?
Amolyt Pharma has raised $210M in total disclosed funding across the rounds on record.
Who has invested in Amolyt Pharma?
Sofinnova Partners, LSP, Novo Ventures, Kurma Partners, OrbiMed, EQT Life Sciences are named among the investors backing Amolyt Pharma.
What was the latest Amolyt Pharma funding round?
The most recent disclosed round is a Series C, announced in January 2023.
Where is Amolyt Pharma based?
Amolyt Pharma is based in Lyon, France.
When did Amolyt Pharma last raise?
The last disclosed Amolyt Pharma round closed in January 2023 at Series C.
Amolyt Pharma totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Lyon below to benchmark round size and investor mix.
